The impact of autoimmune thyroid disease on cognitive and psychiatric disorders: focus on clinical, pre-clinical and molecular studies
European Thyroid Journal · 2025
DOI: 10.1530/etj-24-0406 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Thyroid Journal, 2025. Verfasst von Agnieszka Piekiełko-Witkowska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Postgraduate Medical Education, Centre of Translational Research, Department of Biochemistry and Molecular Biology, Warsaw, Poland. Hauptthemen laut MEDLINE: Mental Disorders, Cognition Disorders, Graves Disease, Thyroiditis, Autoimmune. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Autoimmune thyroid disease (AITD) is the most prevalent organ-specific autoimmune condition, encompassing Graves’ disease (typically linked with hyperthyroidism) and Hashimoto’s thyroiditis (generally associated with hypothyroidism). The growing body of evidence suggests that AITD can interfere with brain function. Here, we review the impact of AITD on cognition, mood, and psychiatric disorders by analysing data from clinical, animal, ex vivo and in vitro studies to reveal the molecular mechanisms by which AITD affects brain function. Most reports indicate a stronger association between cognitive impairments and hyperthyroidism (including AITD-related) than hypothyroidism. Both hypothyroidism and hyperthyroidism are linked with a higher risk of depression. At least some of those effects can be mediated by altered concentrations of T3 (3,3′,5-triiodo-L-thyronine), which regulates gene expression in the brain microenvironment, affecting neurogenesis, angiogenesis, neurotransmitter release, and synaptic transmission. Diminished TSH (thyrotropin) signalling may also impair learning and memory by inhibiting the Wnt5a-β-catenin pathway. Thyroid disorders may also contribute to neurodegeneration by T3-mediated attenuation of amyloid-β elimination or TRH-induced formation of neurofibrillary tangles. Surprisingly, most clinical studies do not specify the immune origin of hypothyroidism or hyperthyroidism, therefore further studies involving large, well-characterised patient cohorts are needed to clarify the relationships between AITD and cognitive impairments and psychiatric disorders. Furthermore, data on the effect of anti-thyroid antibodies on brain function are scarce and inconclusive. Given the association between hyperthyroidism and an increased risk of dementia, cognitive impairment and mood disorders, adequate treatment and careful monitoring of AITD patients are essential to prevent the induction of exogenous hyperthyroidism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre of Postgraduate Medical Education, Centre of Translational Research, Department of Biochemistry and Molecular Biology, Warsaw, Poland.
- Centre of Postgraduate Medical Education, Centre of Translational Research, Department of Clinical Physiology, Warsaw, Poland.
ORCID-Profile: Agnieszka Piekiełko-Witkowska
Zitieren
APA
Piekiełko-Witkowska, A., Duda, M. K., Bogusławska, J., & Mackiewicz, U. (2025). The impact of autoimmune thyroid disease on cognitive and psychiatric disorders: focus on clinical, pre-clinical and molecular studies. European Thyroid Journal. https://doi.org/10.1530/etj-24-0406
Vancouver
Piekiełko-Witkowska A, Duda MK, Bogusławska J, Mackiewicz U. The impact of autoimmune thyroid disease on cognitive and psychiatric disorders: focus on clinical, pre-clinical and molecular studies. European Thyroid Journal. 2025. doi:10.1530/etj-24-0406
BibTeX
@article{PiekiekoWitkowska2025,
author = {Piekiełko-Witkowska, Agnieszka and Duda, Monika K and Bogusławska, Joanna and Mackiewicz, Urszula},
title = {The impact of autoimmune thyroid disease on cognitive and psychiatric disorders: focus on clinical, pre-clinical and molecular studies},
journal = {European Thyroid Journal},
year = {2025},
doi = {10.1530/etj-24-0406}
}
EUVIMED